Challenges in clinical patient management

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Endocrine therapy is a cornerstone of breast cancer treatment, with tamoxifen and aromatase inhibitors (AIs) being key agents.
• Tamoxifen, an estrogen-receptor modulator, has been standard for hormone-responsive breast cancer for decades.
• Third-generation AIs target estrogen biosynthesis, offering an alternative mechanism and safety profile to tamoxifen.

Purpose of the Study:

• To review aromatase inhibitor (AI)-associated side effects in breast cancer treatment.
• To discuss current clinical management strategies for AI-related adverse events, particularly bone health.
• To explore adherence, long-term compliance, and special considerations for elderly patients.

Main Methods:

• Literature review of endocrine therapies for breast cancer.
• Analysis of safety profiles and adverse events associated with aromatase inhibitors.
• Discussion of clinical management strategies and patient adherence.

Main Results:

• Aromatase inhibitors (AIs) have a different safety profile than tamoxifen, with most adverse events being mild to moderate.
• AI-associated side effects are often manageable and comparable to menopausal symptoms.
• Bone health management is a critical aspect of AI therapy.

Conclusions:

• Aromatase inhibitors are effective endocrine therapies for hormone-responsive breast cancer with a manageable side effect profile.
• Proactive management of side effects, especially bone health, is crucial for long-term adherence.
• Strategies to improve patient adherence and address specific populations like the elderly are important for successful treatment outcomes.